跳至主要内容
临床试验/IRCT20200408046990N11
IRCT20200408046990N11已完成2 期

Evalution of oral nano-curcumin formulation efficacy in prevention of cisplatin induced nephrotixicity in cancer patients

Mashhad University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
All

入选标准

  • Patients with cancer and candidates for chemotherapy with regimen containing cisplatin at a dose of 70mg/m2 every three weeks or 40mg/m2 weekly Patient age above 18 years and below 70 years GFR>60 ml/min At the start of chemotherapyNormal liver function Normality of patients' CBC

排除标准

  • Allergy to curcuminPatient dissatisfactionReduction of patient's GFR below 45ml/min during treatmentReceiving other nephrotoxic drugs such as aminoglycosides, amphotericin, vancomycin Patients with chronic heart failure EF<60%Patients with untreated hypothyroidism or hyperthyroidismPatients with active infectionReceiving anti-inflammatory and antioxidant drugs at the same timeUnfavorable health status (PS<70%) based on karnofsky index

研究者

相似试验

Observing the effect of nanocurcumin oral product in... | 临床试验